Ads
related to: fda approved for idiopathic hypersomnia- IH Treatment
Learn More About An Idiopathic
Hypersomnia Treatment Option.
- FAQs
Get Answers to Frequently Asked
Questions About Hypersomnia.
- Talking to Your Doctor
Talk To Your Doctor And Find Out If
Treatment May Be Right for You.
- Unlock Support
Get The Latest News on Information
About Idiopathic Hypersomnia.
- Clinical Trial Results
Learn More About Clinical Studies
for a Hypersomnia Treatment.
- Explore Patient Resources
Discover Financial Support & Other
Important Resources For You.
- IH Treatment
Search results
Results From The WOW.Com Content Network
In August 2021, low-sodium oxybate (Xywav) became the first U.S. FDA-approved treatment for idiopathic hypersomnia. [5] Wake-promoting medications used in narcolepsy are also commonly used off-label to help manage the excessive daytime sleepiness of IH.
Xywav is indicated for the treatment of cataplexy or excessive daytime sleepiness in people aged seven years of age and older with narcolepsy; [2] [6] and for idiopathic hypersomnia. [ 6 ] [ 7 ] Side effects
A 2021 Cochrane study determined that the evidence is inadequate to definitively determine the efficacy of clarithromycin in the management of idiopathic hypersomnia. [10] The American Academy of Sleep Medicine's 2021 clinical practice guidelines conditionally suggested its use, especially for those who don't respond to other therapies.
Hypersomnia can be secondary to disorders such as clinical depression, multiple sclerosis, encephalitis, epilepsy, or obesity. [17] Hypersomnia can also be a symptom of other sleep disorders, like sleep apnea. [17] It may occur as an adverse effect of taking certain medications, of withdrawal from some medications, or of substance use. [17]
It may also be effective in reducing excessive daytime sleepiness while improving vigilance in primary hypersomnias, such as idiopathic hypersomnia. [6] The drug has also been used in hepatic encephalopathy. It may have beneficial short‐term effects in people with cirrhosis, but there is no evidence for long-term benefits. [10]
In early 2023, the U.S. Food and Drug Administration (FDA) granted accelerated approval to a new Alzheimer’s drug called Leqembi. (Biogen, a biotechnology company, and Eisai, a pharmaceutical ...
Ads
related to: fda approved for idiopathic hypersomnia